Hexabrix Key Clinical Review Le Feuvre, 2006

Slides:

Advertisements

Similar presentations

University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.

Advertisements

Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.

CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.

Author: Moldovan Carmen Co-authors: Opincariu Diana Balan Daniel University of Medicine and Pharmacy Tg. Mures Cardiology Clinic, Mures Emergency Clinical.

1 SIROLIMUS-ELUTING STENTS FOR IN-STENT RESTENOSIS TREATMENT IN 278 UNSELECTED PATIENTS: INSIGHTS ON LONG-TERM OUTCOMES FROM A LARGE TWO-CENTER REGISTRY.

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.

AICT 2010-Athens Interventional Cardiovascular Therapeutics XI 8-9 OCTOBER 2010 Divani Caravel Hotel, Αthens EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT.

Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: an International Randomized Evaluation (STEEPLE) Presented.

PRODIGY Objective Study Design Primary Composite Endpoint

Clinical Trial Results. org Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary.

Trial Design Issues Associated with Evaluation of Distal Protection Devices in Diseased Saphenous Vein Grafts Bram D. Zuckerman, MD, FACC Medical Officer,

Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.

LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,

LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,

Hexabrix Key Clinical Review Liss, 2006 Mid-Year Sales Meeting Bloomington, IN July 13 th – 17 th.

¨ 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin.

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?

Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.

Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.

End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to

Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.

1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.

Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.

Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,

The OPTIMAX first-in-man study Mid-term clinical outcome of Titanium-Nitride-Oxide-coated Cobalt Chromium stents in patients with de novo coronary artery.

From: Risks of Cardiovascular Adverse Events and Death in Patients with Previous Stroke Undergoing Emergency Noncardiac, Nonintracranial Surgery:The Importance.

The BVS-SAVE Italian registry: Bioresorbable Vascular Scaffolds

Should we care about post-procedural troponin in elective coronary stenting ? Michel Zeitouni, Johanne Silvain*, Mathieu Kerneis, Olivier Barthelemy,

Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.

Damian Gimpel Waikato Cardiothoracic Unit Journal Club

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.

TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.

Ischaemic Heart Disease Acute Coronary Syndrome

Study Design AMI <12 hours, any age, cardiogenic shock excluded

Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study Xin Zheng,

Hexabrix Key Clinical Review Mehran, 2009

HEXABRIX Philippe HAVARD

Introduction The American Journal of Medicine

Diabetes mellitus in patients undergoing percutaneous drug-eluting stent implantation: short and long-term results Claudio Moretti, M.D. Division of Cardiology,

Statins Evaluation in Coronary procedUres and REvascularization

European Heart Association Journal 2007 April

American College of Cardiology Presented by Dr. Stephan Windecker

European Society of Cardiology 2003

REALITY: 8 month results

Preventive Angioplasty in Myocardial Infarction Trial

The American College of Cardiology Presented by Dr. Raimund Erbel

American Heart Association Presented by Dr. Julinda Mehilli

Impact of Platelet Reactivity Following Clopidogrel Administration

Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.

Role of Stenting in Acute MI: PAMI Stent Pilot Trial

DECLARE-TIMI 58.

Presented at TCT 2006.

Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J

Maintenance of Long-Term Clinical Benefit with

DEScover: One-Year Clinical Results

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.

Atlantic Cardiovascular Patient Outcomes Research Team

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

The American College of Cardiology Presented by Dr. A. Abazid

NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.

TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.

Javier Escaned et al. JCIN 2018;11:

Section C: Clinical trial update: Oral antiplatelet therapy

Presentation transcript:

Hexabrix Key Clinical Review Le Feuvre, 2006 Mid-Year Sales Meeting Bloomington, IN July 13th – 17th

Hexabrix Key Clinical Review Title: Cardiac Events After Low Osmolar Ionic or Isosmolar NonIonic Contrast Media Utilization in the Current Era of Coronary Angioplasty Main Author: Claude Le Feuvre Publication: Catheterization and Cardiovascular Interventions Date: 2006

Hexabrix Key Clinical Review Study Objective(s): To compare Visipaque and Hexabrix in the current era of (PCI), using clopidogrel, enoxaparine, direct stenting, and drug eluting stent.

Hexabrix Key Clinical Review Patient Population Details: 498 Consecutive Patients over 6 months First, third & fifth months patients received Hexabrix (267) Second, fourth and sixth months patients received Visipaque (231). No significant difference among baseline characteristics.

Hexabrix Key Clinical Review Primary & Secondary Endpoints: Primary: The cumulative rate of in-hospital major adverse clinical events (MACE). Secondary: The rate of angiographic or procedural complications

Hexabrix Key Clinical Review Outcomes & Results: The primary composite end point occurred less frequently in the Hexabrix group. By 30 days, the cumulative rate of the primary composite endpoint remained lower in the Hexabrix group. Thrombus-related events were more frequent with Visipaque than with Hexabrix.

Hexabrix Key Clinical Review 1 2 3 4 5 6 % Large thrombus Target vessel occlusion Iodixanol Ioxaglate p = 0.0001 p = 0.003

Hexabrix Key Clinical Review Other Important Notes: All patients received aspirin and enoxaparin. MACE was defined as cardiac death, recurrent nonfatal acute myocardial infarction, emergency CABG or repeat PCI for documented ischemic ECG changes, stroke, or systemic thromboembolic event. Clinical outcomes were assessed at hospital discharge and by telephone at 30 days.

Hexabrix Key Clinical Review Role Play (15 min) Pairs of 3 (MCP, MD & Observer) Each MCP detail the paper to group Be sure to summarize the key points

Hexabrix Key Clinical Review Examples of use in the field?